Updated:
Biosensors International Group
Biosensors International Group maintains its primary footprint in Singapore, with additional offices in Bengaluru and Mumbai. Its product architecture centers...
Biosensors International Group
Biosensors International Group maintains its primary footprint in Singapore, with additional offices in Bengaluru and Mumbai. Its product architecture centers on Biolimus A9, deployed across stent and balloon platforms that include the BioFreedom Ultra polymer-free drug-eluting stent, the BioMatrix Alpha stent with biodegradable polymer, and the Allegra TAVI system with a self-expanding nitinol frame. The portfolio also covers Rise NC and Rise SC balloon catheters plus the Biomc microcatheter. Devices reach the US, French, and broader Asian markets through direct sales units and partners.
General information
Firm type
Asset Manager
Location
Region
Asia
Country
Singapore
City
Singapore
Corporate office
Singapore
Additional offices
Bengaluru · Mumbai
Sector focus
Frequently asked questions
What is Biosensors International Group's core technology platform?
The firm builds its entire interventional cardiology portfolio around Biolimus A9, a proprietary anti-proliferative agent derived from sirolimus. This single compound appears across the BioFreedom, BioMatrix, and Allegra product families. The polymer-free BioFreedom platform targets high-bleeding-risk patients, while BioMatrix Alpha pairs the same drug with a bioabsorbable polymer.
Does Biosensors operate as a fund or an operating company?
The available public materials present Biosensors International as a medical-device operating company with a direct commercial footprint, not as a pooled investment fund. Its website lists products, clinical programs, and geographic sales offices in the US and France. No fund structure, investor portal, or fundraising activity is disclosed on the scraped homepage or broader site.
Which markets does Biosensors serve directly?
The firm maintains separate web presences for its US and French subsidiaries, suggesting direct sales operations in those countries. Physical offices are confirmed in Singapore, Bengaluru, and Mumbai. The Allegra TAVI system is marketed in Europe and select Asian countries, indicating a wider regional distribution network beyond the three named office locations.
What clinical differentiator does BioFreedom claim relative to polymer-coated stents?
BioFreedom Ultra uses a micro-structured abluminal surface to deliver Biolimus A9 without a polymer carrier. In the LEADERS FREE trial program, the platform demonstrated superior safety versus bare-metal stents in high-bleeding-risk patients treated with one month of dual antiplatelet therapy. The absence of polymer eliminates a potential trigger for chronic inflammation and late stent thrombosis.
Who runs investment and strategy decisions at Biosensors International?
No named principals, executives, or board members are publicly surfaced on the firm's corporate website or in the available Altss research record. The organization's governance structure and investment decision-making process remain opaque to external observers without deeper primary sourcing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: